Expertise in
10
conditions

Dr. Jeffrey D. Crawford

Vascular Surgery
Legacy Medical Group-Vascular At Salmon Creek
2101 NE 139th St, 
Vancouver, WA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Expertise in
10
conditions
Legacy Medical Group-Vascular At Salmon Creek
2101 NE 139th St, 
Vancouver, WA 

Overview

Jeffrey Crawford is a Vascular Surgeon practicing medicine in Vancouver, Washington.

Dr. Crawford is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Febrile Neutropenia, Peripheral Artery Disease, Thoracic Aortic Aneurysm, Retinopathy Arteriosclerotic, and Carotid Artery Surgery.

He is actively involved in clinical research, co-authoring 129 peer reviewed articles and participating in 52 clinical trials. Dr. Crawford is currently accepting new patients.

Specialties

Vascular Surgery

Licenses

Vascular Surgery in OR

Hospital Affiliations

Legacy Emanuel Medical Center
Legacy Meridian Park Medical Center
Legacy Mount Hood Medical Center
Legacy Good Samaritan Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser
  • EPO
  • HMO
  • POS
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 6 Less Insurance Carriers -

Locations

Legacy Medical Group-Vascular at Salmon Creek
2101 NE 139th St, Vancouver, WA 98686

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

52 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
View 8 Less Clinical Trials

129 Total Publications

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 28, 2026
Similar Doctors
Expertise in
10
conditions
Dr. Sherene N. Shalhub
Vascular Surgery
Expertise in
10
conditions
Dr. Sherene N. Shalhub
Vascular Surgery
Referral may be required

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (15.6 miles away)
503-494-7593
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Sherene Shalhub is a Vascular Surgeon practicing medicine in Portland, Oregon. Dr. Shalhub is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Vascular Ehlers-Danlos Syndrome (VEDS), Thoracic Aortic Aneurysm, Aortic Dissection, Ehlers-Danlos Syndrome (EDS), and Angioplasty. Dr. Shalhub is currently accepting new patients.

Expertise in
14
conditions
Dr. Gregory L. Moneta
Vascular Surgery
Expertise in
14
conditions
Dr. Gregory L. Moneta
Vascular Surgery
Referral may be required

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (15.6 miles away)
503-494-7593
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gregory Moneta is a Vascular Surgeon practicing medicine in Portland, Oregon. Dr. Moneta is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Abdominal Aortic Aneurysm (AAA), Thoracic Aortic Aneurysm, Peripheral Artery Disease, Carotid Artery Surgery, and Aneurysm Repair. Dr. Moneta is currently accepting new patients.

Expertise in
11
conditions
Dr. Alejandro B. Perez
Vascular Surgery
Expertise in
11
conditions
Dr. Alejandro B. Perez
Vascular Surgery
Referral may be required
Before you request
4400 Northeast Halsey Street, Building 1, 
Portland, OR 
 (12.9 miles away)
503-962-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alejandro Perez is a Vascular Surgeon practicing medicine in Portland, Oregon. Dr. Perez is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Primary Intestinal Lymphangiectasia, Meige Disease, Lymphangiectasis, and Lymphedema. Dr. Perez is currently accepting new patients.

Frequently Asked Questions about Dr. Jeffrey D. Crawford

How do I make an appointment with Dr. Jeffrey D. Crawford?

You can book an appointment with Dr. Jeffrey D. Crawford by calling their office at 360-487-2800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeffrey D. Crawford a top-rated expert for Febrile Neutropenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeffrey D. Crawford is classified as an Elite expert for Febrile Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeffrey D. Crawford specialize in?

While Dr. Jeffrey D. Crawford is a Vascular Surgery, they have specific expertise in Febrile Neutropenia, Peripheral Artery Disease, and Thoracic Aortic Aneurysm. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Vascular Surgery.

Does Dr. Jeffrey D. Crawford participate in research or clinical trials?

Yes. Dr. Jeffrey D. Crawford has published 129 articles and abstracts on conditions like Febrile Neutropenia. You can view a list of Dr. Jeffrey D. Crawford's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jeffrey D. Crawford accept my insurance?

Dr. Jeffrey D. Crawford accepts most major insurance plans, including Blue Cross Blue Shield and BridgeSpan. We recommend calling the office directly at 360-487-2800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Crawford's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile